Insider Trading June 12, 2026 03:37 PM

HRT Financial LP Fully Exits Aditxt Position Following $39,668 Share Sale

The 10% shareholder liquidates its entire stake as the biotech firm navigates a severe valuation collapse and strategic restructuring.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ADTX

HRT FINANCIAL LP, which previously held a 10% ownership stake in Aditxt, Inc., executed a complete divestiture of its position by selling 2,833,463 shares of common stock on June 11, 2026. The transaction, valued at $39,668 based on a sale price of $0.014 per share, marks the total exit of the institutional investor from the biotech company. This sale follows a period of extreme volatility for Aditxt, with its stock price experiencing a 79% weekly decline and a near-total year-to-date collapse. Amid this financial turbulence, Aditxt is undertaking significant corporate restructuring, including a major subsidiary listing, leadership changes, and compliance measures.

HRT Financial LP Fully Exits Aditxt Position Following $39,668 Share Sale
ADTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • HRT FINANCIAL LP liquidated 2,833,463 shares of Aditxt, Inc. at $0.014 per share, fully exiting its 10% ownership position and leaving no remaining stake in the company.
  • Aditxt is undergoing significant corporate restructuring, including the SPAC listing of subsidiary Ignite Proteomics LLC, the appointment of Jeffrey M. Busch as interim CEO, and the execution of a 1-for-27 reverse stock split.
  • The biotech firm has secured compliance with Nasdaq listing standards based on a reported stockholders' equity of $3,953,682 and raised $1.25 million through the issuance of senior unsecured notes maturing in September 2026.

HRT FINANCIAL LP has completely liquidated its remaining holdings in Aditxt, Inc., concluding its relationship with the biotechnology firm. The institutional investor sold 2,833,463 shares of common stock on June 11, 2026, at a price of $0.014 per share. This transaction resulted in a total realized value of $39,668. According to a Form 4 filing submitted to the Securities and Exchange Commission on June 12, 2026, the disposal of these final shares means HRT FINANCIAL LP no longer maintains any ownership interest in Aditxt, Inc.


The divestiture occurs against a backdrop of severe market pressure for the company. Aditxt shares have experienced a 79% decline over the previous week, dropping to $0.01. This rapid depreciation has compressed the company's market capitalization to approximately $0.01 million. Broader performance metrics indicate even steeper losses, with the stock suffering a 99.99% decline year-to-date. Independent financial analysis from InvestingPro rates the company's financial health as "WEAK," highlighting significant operational vulnerabilities.


In response to these challenges, Aditxt has announced a series of strategic and operational adjustments. The company revealed that its subsidiary, Ignite Proteomics LLC, will become a publicly traded entity through a special purpose acquisition company transaction. This deal assigns an implied equity value of approximately $150 million to Ignite. To oversee these developments, Aditxt appointed Jeffrey M. Busch as interim CEO, a role he will hold concurrently with his position as CEO of Ignite Proteomics.


Further structural changes include the implementation of a 1-for-27 reverse stock split, effective May 18, 2026, following approval from stockholders. On the capital front, Aditxt disclosed a private placement of senior unsecured notes valued at $1.25 million. These notes carry an annual interest rate of 10% and are scheduled to mature on September 30, 2026.


Additionally, the company confirmed that it has regained compliance with Nasdaq listing standards. This compliance was verified through a letter from The Nasdaq Stock Market LLC, which cited the company's annual report showing stockholders' equity of $3,953,682. These actions collectively signal a period of intensive restructuring and financial stabilization efforts for Aditxt.

Risks

  • Aditxt faces severe valuation pressure, evidenced by a 79% weekly stock decline and a 99.99% year-to-date collapse, which has reduced its market capitalization to approximately $0.01 million.
  • Independent financial assessments rate the company's financial health as "WEAK," indicating substantial operational and fiscal vulnerabilities that may impact future stability.
  • The execution of a 1-for-27 reverse stock split and reliance on private debt placements highlight potential liquidity constraints and the need for aggressive capital restructuring to maintain market compliance.

More from Insider Trading

AMD Chief Executive Lisa Su Executes $57.6 Million Stock Sale Under Pre-Arranged Trading Plan Jun 12, 2026 Guardant Health CIO Kalia Disposes of $652K in Stock Amid Regulatory Milestones Jun 12, 2026 Datavault AI Executive Insider Sale Highlights Recent Corporate Developments Jun 12, 2026 Mink Brook Asset Management Acquires Additional DLHC Shares Amid Fiscal Challenges Jun 12, 2026 DoorDash Director Ashley Still Offloads $178,767 in Shares Amid Market Volatility Jun 12, 2026